Drug
Ziftomenib
Ziftomenib: highest development phase Phase 2, developed by Kura Oncology, Inc., Kyowa Kirin. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Kura Oncology, Inc., Kyowa Kirin
Trials
| Drug | Phase | Indication |
|---|---|---|
| ziftomenib NCT07623616 | Phase 2 | Acute Myeloid Leukemia (AML) |
| Ziftomenib NCT07929740 | Phase 1 | Myelodysplastic Syndrome (MDS)/AML |
Latest
No recent events.
Follow Ziftomenib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.